Potassium Chloride Extended Release Tablets
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-24-R-0013
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Defense Logistics Agency (DLA) Troop Support has issued a solicitation, identified as SPE2D2-24-R-0013, for the procurement of Potassium Chloride Extended Release Tablets. This opportunity is classified under NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further designated by Product Service Code 6505, indicating a focus on medical and pharmaceutical products.
The primary objective of this procurement is to secure a reliable supply of Potassium Chloride Extended Release Tablets for federal use, supporting the health and medical readiness of military personnel and other authorized recipients. The scope of the solicitation encompasses the manufacturing and delivery of these pharmaceutical products in accordance with federal standards and specifications, ensuring consistent quality, efficacy, and safety throughout the contract lifecycle.
DLA Troop Support, a federal office, serves as the contracting entity for this requirement. Interested contractors should note that the solicitation is managed by two primary points of contact: Ryan Guarnere ([email protected], 215-737-2571) and Jason Wray ([email protected], 215-737-0614). These contacts can provide further clarification regarding technical requirements, submission procedures, and compliance expectations.
The solicitation was originally posted on March 28, 2025, with a response deadline of July 11, 2024. Although the notice status is currently marked as inactive, contractors are encouraged to review the opportunity details and associated attachments available on SAM.gov (Opportunity ID: 847133d3021d4032a758dd19f0f7deac) for comprehensive requirements and instructions. There are twelve attachments linked to the notice, which may contain specifications, terms, and other pertinent documentation.
No information is provided regarding set-aside requirements, special considerations, or specific procurement types (such as small business set-asides or sole source awards). Contractors specializing in pharmaceutical manufacturing, particularly those with experience in producing extended release formulations, should assess their capabilities against the stated requirements and review all available documentation to determine alignment with their expertise and compliance capacity.
This procurement represents a critical supply chain activity for federal medical support, and contractors are expected to maintain high standards of quality and reliability throughout the duration of the contract. All elements related to product specifications, delivery schedules, and regulatory compliance will remain constant and central to the successful fulfillment of this requirement.
Documents12